Pharmacodynamic and pharmacokinetic evaluation in man of the new sympathomimetic amezinium.

Blood pressure, ECG and plasma concentration were determined for up to 12 h following single i.v. (10 mg) and oral (20 mg) doses of amezinium (Regulton) in 8 healthy, male volunteers.

Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.

The absolute bioavailability and pharmacokinetics of 4-amino-6-methoxy-1-phenyl-pyridazinium methyl sulfate (amesiniummetilsulfate, LU 1631, Regulton), in the following briefly called amezinium, were examined following i.v. injection (10 mg) and single p.

Determination of amezinium in body fluids.

Possible approaches to the determination in body fluids of 4-amino-6-methoxy-1-phenyl-pyridazinium methyl sulfate (ameziniummetilsulfate, LU 1631, Regulton), in this study briefly called amezinium, are investigated and the methods developed on the basis of results obtained in pilot experiments described. These methods, which are primarily based on radioactive tracer techniques, allow both labelled and unlabelled amezinium to be determined in urine, bile, blood, and plasma in concentrations down to about 2 n/ml. Relative standard deviations of 0.